Positive surprises with Lexicon’s Zynquista and DBV’s Viaskin Peanut show that you can never entirely write biotech off.
With the EU regulator already reviewing two coronavirus vaccines, could it beat the US FDA to the punch?
As a Covid-19 vaccine exclusivity and senior management storm engulfs Curevac, the German mRNA specialist insists it’s just conjecture and coincidence.
The unexpected approval of Vyondys 53 followed an FDA power struggle, and turned on a vague commitment from Sarepta, it has emerged.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
Weaker than expected generic erosion of its key Suboxone film product has allowed Indivior to raise full-year guidance.